MD Anderson and Jazz Pharmaceuticals collaborate to evaluate treatment options for hematol

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news